Combining Immunotherapy With Radiation Oncology in NSCLC

Commentary
Video

Terrence T. Sio, MD, MS, emphasizes multidisciplinary collaboration for treating patients with NSCLC who may require more than 1 type of therapy.

In a conversation with CancerNetwork®, Terence T. Sio, MD, MS, highlighted radiation oncology treatment decision-making strategies for patients with non–small cell lung cancer (NSCLC), including for those who may be eligible to receive immunotherapy.

According to Sio, a professor of radiation oncology at Mayo Clinic in Phoenix, Arizona, it is crucial to consider potential toxicities, such as pneumonia and factors such as tumor size when administering radiation therapy to patients with NSCLC. Additionally, he emphasized multidisciplinary collaboration across different departments at his institution to optimize treatment courses for those who may require more than 1 type of therapy.


Transcript:

There is a lot of very good biology that is now being used for helping our patients and getting targeted [treatment] for that cancer. These are very specific treatments that may involve targets such as EGFR or KRAS mutations. There are now also new advances on the horizon [involving] combining immunotherapy, too.

These medications, and how the treatments are needed to be used for our patients, make a difference in terms of the decisions that we may make as a radiation oncologist for our [patients with] lung cancer. Depending on how big the tumor may be and the number of lung and heart tissues that will be exposed to radiation therapy, it is important to balance the risks. How likely is it for an injury like pneumonia or what we call radiation-induced pneumonitis to happen in this setting? It is very important [to have] multidisciplinary treatment and consultation with our surgeons and our medical oncologists. At our institutions, tumor boards are being held at regular intervals weekly. There are a lot of cross disciplinary discussions among different doctors to make sure that we're providing the best method for helping our patients who will very likely need more than 1 treatment, or [more than] 1 doctor's care if they have stage III non–small cell lung cancer.

Recent Videos
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Generally, the communication in academic oncology institutions is favorable; however, when oncologists and pathologists become busy, specimens may be sent to reference laboratories.
Hydration and a healthy, well-balanced diet may mitigate fatigue among patients undergoing treatment for cancer.
The medical characteristics of a patient may heavily factor into the selection of tyrosine kinase inhibition for the treatment of chronic myeloid leukemia.
Bland foods, such as crackers and chicken noodle soup, as well as fluids with electrolytes, may help stave off treatment-related nausea.
The toxicity profile of interferon and the limited availability of transplantation established a need for TKI development for chronic myeloid leukemia.
Predictors of response have a significant effect on clinical decision-making because they may help oncologists select the best treatment for specific patients.
Related Content